Kleven M S, Koek W
Centre de Recherche Pierre Fabre, Castres, France.
J Pharmacol Exp Ther. 1996 Feb;276(2):388-97.
A conflict procedure in pigeons was used to characterize the antipunishment effects of the putative mixed 5-hydroxytryptamine (5-HT)1A agonist/5-HT2A/2C antagonists WY 50,324, CGS 18102A, LEK 8804 and FG 5974 and to further investigate interactions between the antipunishment effects of the 5-HT1A agonists buspirone and 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] administered in combination with the mixed 5-HT2A/2C antagonist ritanserin and the alpha 1 antagonist prazosin. The 5-HT1A agonists, buspirone and 8-OH-DPAT, which lack affinity for 5-HT2A/2C receptors, produced dose-related increases in punished responding. Of the compounds with a mixed binding profile, only WY 50,324 showed effects that were comparable to those observed after 8-OH-DPAT, whereas FG 5974 and CGS 18102A exhibited limited effects on punished responding, and LEK 8804 was ineffective. Administration of a relatively low, behaviorally active dose of ritanserin (0.16 mg/kg) significantly enhanced the potency of 8-OH-DPAT and buspirone to increase punished responding from 8 to 50-fold without altering their effects on unpunished responding. Importantly, ritanserin failed to increase the number of doses of 8-OH-DPAT that significantly increased punished responding. In contrast, prazosin (2.5 mg/kg) significantly enhanced the potency and increased the number of doses of buspirone exerting significant effects on punished responding, but did not alter the effects of 8-OH-DPAT. Taken together, the results neither explain the suggested greater efficacy in producing anxiolytic effects of compounds with putative mixed 5-HT1A agonist and 5-HT2A/2C antagonist properties, nor confirm a proposed interaction between alpha1 adrenoreceptors and 5-HT1A agonists in preclinical tests of anxiolytic activity.
采用鸽子冲突程序来表征假定的5-羟色胺(5-HT)1A激动剂/5-HT2A/2C拮抗剂WY 50324、CGS 18102A、LEK 8804和FG 5974的抗惩罚作用,并进一步研究5-HT1A激动剂丁螺环酮和8-OH-DPAT [8-羟基-2-(二正丙基氨基)四氢萘]与5-HT2A/2C拮抗剂利坦色林和α1拮抗剂哌唑嗪联合给药时抗惩罚作用之间的相互作用。对5-HT2A/2C受体缺乏亲和力的5-HT1A激动剂丁螺环酮和8-OH-DPAT,可使受惩罚反应呈剂量相关增加。在具有混合结合特性的化合物中,只有WY 50324的作用与8-OH-DPAT给药后观察到的作用相当,而FG 5974和CGS 18102A对受惩罚反应的影响有限,LEK 8804则无效。给予相对低剂量且具有行为活性的利坦色林(0.16 mg/kg)可显著增强8-OH-DPAT和丁螺环酮增加受惩罚反应的效力,使其提高8至50倍,且不改变它们对未受惩罚反应的影响。重要的是,利坦色林未能增加能显著增加受惩罚反应的8-OH-DPAT剂量数。相比之下,哌唑嗪(2.5 mg/kg)显著增强了丁螺环酮对受惩罚反应产生显著作用的效力并增加了其有效剂量数,但未改变8-OH-DPAT的作用。综上所述这些结果,既无法解释具有假定的5-HTIA激动剂和5-HT2A/2C拮抗剂特性的化合物在产生抗焦虑作用方面所显示的更高疗效,也无法在抗焦虑活性的临床前试验中证实α1肾上腺素能受体与5-HT1A激动剂之间存在假定的相互作用。